drugset / Trial / NCT03691207
A Study Of AL101In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 2, non comparative, open label, multicenter study of AL101 in patients with recurrent or metastatic ACC who harbor NOTCH 1,2,3,4 activating mutations.
Timeline
- Start
- 2018-12-14
- Primary completion
- 2022-07-15
- Completion
- 2022-12-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AL101 | Small molecule | 4 mg | Intravenous |
| Subject | AL101 | Small molecule | 6 mg | Intravenous |